A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation positive non-squamous, advanced non-small-cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B.
Afatinib;Carboplatin;Osimertinib;Pemetrexed
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation positive non-squamous, advanced non-small-cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B. ### Output: Afatinib;Carboplatin;Osimertinib;Pemetrexed